ZA200206591B - Protecting molecules in biologically derived compositions while treating with broad-spectrum pulsed light. - Google Patents
Protecting molecules in biologically derived compositions while treating with broad-spectrum pulsed light. Download PDFInfo
- Publication number
- ZA200206591B ZA200206591B ZA200206591A ZA200206591A ZA200206591B ZA 200206591 B ZA200206591 B ZA 200206591B ZA 200206591 A ZA200206591 A ZA 200206591A ZA 200206591 A ZA200206591 A ZA 200206591A ZA 200206591 B ZA200206591 B ZA 200206591B
- Authority
- ZA
- South Africa
- Prior art keywords
- composition
- biomolecule
- biologically derived
- albumin
- interest
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 156
- 238000011282 treatment Methods 0.000 claims description 68
- 238000000034 method Methods 0.000 claims description 61
- 102000009027 Albumins Human genes 0.000 claims description 48
- 108010088751 Albumins Proteins 0.000 claims description 48
- 241000700605 Viruses Species 0.000 claims description 40
- 239000003053 toxin Substances 0.000 claims description 30
- 231100000765 toxin Toxicity 0.000 claims description 30
- 108700012359 toxins Proteins 0.000 claims description 30
- 244000052769 pathogen Species 0.000 claims description 28
- 102000004169 proteins and genes Human genes 0.000 claims description 25
- 108090000623 proteins and genes Proteins 0.000 claims description 24
- 102000004190 Enzymes Human genes 0.000 claims description 21
- 108090000790 Enzymes Proteins 0.000 claims description 21
- 230000001717 pathogenic effect Effects 0.000 claims description 19
- 239000000463 material Substances 0.000 claims description 15
- 230000004071 biological effect Effects 0.000 claims description 14
- 239000000126 substance Substances 0.000 claims description 13
- 230000002779 inactivation Effects 0.000 claims description 11
- 241000894006 Bacteria Species 0.000 claims description 10
- 210000004027 cell Anatomy 0.000 claims description 10
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 8
- 230000003612 virological effect Effects 0.000 claims description 7
- 241001465754 Metazoa Species 0.000 claims description 6
- 230000015556 catabolic process Effects 0.000 claims description 6
- 238000006731 degradation reaction Methods 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 238000011084 recovery Methods 0.000 claims description 6
- 230000009467 reduction Effects 0.000 claims description 6
- 241000283690 Bos taurus Species 0.000 claims description 4
- 241000714259 Human T-lymphotropic virus 2 Species 0.000 claims description 4
- 102000004877 Insulin Human genes 0.000 claims description 4
- 108090001061 Insulin Proteins 0.000 claims description 4
- 239000001888 Peptone Substances 0.000 claims description 4
- 108010080698 Peptones Proteins 0.000 claims description 4
- 230000000593 degrading effect Effects 0.000 claims description 4
- AIUDWMLXCFRVDR-UHFFFAOYSA-N dimethyl 2-(3-ethyl-3-methylpentyl)propanedioate Chemical class CCC(C)(CC)CCC(C(=O)OC)C(=O)OC AIUDWMLXCFRVDR-UHFFFAOYSA-N 0.000 claims description 4
- 229940125396 insulin Drugs 0.000 claims description 4
- 235000019319 peptone Nutrition 0.000 claims description 4
- 229940066779 peptones Drugs 0.000 claims description 4
- 231100000331 toxic Toxicity 0.000 claims description 4
- 230000002588 toxic effect Effects 0.000 claims description 4
- 241000701022 Cytomegalovirus Species 0.000 claims description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 3
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 3
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 3
- 102000004338 Transferrin Human genes 0.000 claims description 3
- 108090000901 Transferrin Proteins 0.000 claims description 3
- 238000004113 cell culture Methods 0.000 claims description 3
- 229920000669 heparin Polymers 0.000 claims description 3
- 229960002897 heparin Drugs 0.000 claims description 3
- 208000005252 hepatitis A Diseases 0.000 claims description 3
- 208000002672 hepatitis B Diseases 0.000 claims description 3
- 210000004962 mammalian cell Anatomy 0.000 claims description 3
- 239000012581 transferrin Substances 0.000 claims description 3
- 241000710780 Bovine viral diarrhea virus 1 Species 0.000 claims description 2
- 241000233866 Fungi Species 0.000 claims description 2
- 208000005176 Hepatitis C Diseases 0.000 claims description 2
- 206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 claims description 2
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 claims description 2
- 206010051511 Viral diarrhoea Diseases 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 238000000855 fermentation Methods 0.000 claims description 2
- 230000004151 fermentation Effects 0.000 claims description 2
- 208000006454 hepatitis Diseases 0.000 claims description 2
- 231100000283 hepatitis Toxicity 0.000 claims description 2
- 239000002510 pyrogen Substances 0.000 claims description 2
- 230000009261 transgenic effect Effects 0.000 claims description 2
- 229960005486 vaccine Drugs 0.000 claims description 2
- 230000002477 vacuolizing effect Effects 0.000 claims description 2
- 239000013603 viral vector Substances 0.000 claims description 2
- 241000701931 Canine parvovirus Species 0.000 claims 2
- 108010035532 Collagen Proteins 0.000 claims 2
- 102000008186 Collagen Human genes 0.000 claims 2
- 208000031886 HIV Infections Diseases 0.000 claims 2
- 241000713340 Human immunodeficiency virus 2 Species 0.000 claims 2
- 229920001436 collagen Polymers 0.000 claims 2
- 102100022641 Coagulation factor IX Human genes 0.000 claims 1
- 108010076282 Factor IX Proteins 0.000 claims 1
- 108010054218 Factor VIII Proteins 0.000 claims 1
- 102000001690 Factor VIII Human genes 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 claims 1
- 102000029797 Prion Human genes 0.000 claims 1
- 108091000054 Prion Proteins 0.000 claims 1
- 239000004019 antithrombin Substances 0.000 claims 1
- 229960005188 collagen Drugs 0.000 claims 1
- 229940088598 enzyme Drugs 0.000 claims 1
- 229960004222 factor ix Drugs 0.000 claims 1
- 229960000301 factor viii Drugs 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 239000010453 quartz Substances 0.000 description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 238000005286 illumination Methods 0.000 description 9
- 108010071390 Serum Albumin Proteins 0.000 description 8
- 102000007562 Serum Albumin Human genes 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 7
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 238000012545 processing Methods 0.000 description 7
- 238000004448 titration Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- -1 nucleic acid lipids Chemical class 0.000 description 6
- 239000013077 target material Substances 0.000 description 6
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 5
- 102000013563 Acid Phosphatase Human genes 0.000 description 5
- 108010051457 Acid Phosphatase Proteins 0.000 description 5
- 239000008367 deionised water Substances 0.000 description 5
- 229910021641 deionized water Inorganic materials 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 230000000415 inactivating effect Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 230000004907 flux Effects 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 229910052594 sapphire Inorganic materials 0.000 description 4
- 239000010980 sapphire Substances 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 241000228245 Aspergillus niger Species 0.000 description 3
- 241000450599 DNA viruses Species 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000000120 cytopathologic effect Effects 0.000 description 3
- 238000007865 diluting Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 241000194103 Bacillus pumilus Species 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000013043 chemical agent Substances 0.000 description 2
- 230000001010 compromised effect Effects 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 238000005202 decontamination Methods 0.000 description 2
- 230000003588 decontaminative effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000035931 haemagglutination Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 230000002186 photoactivation Effects 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 239000001974 tryptic soy broth Substances 0.000 description 2
- 108010050327 trypticase-soy broth Proteins 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 229910052724 xenon Inorganic materials 0.000 description 2
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 2
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 241000701242 Adenoviridae Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241000193470 Clostridium sporogenes Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000353621 Eilat virus Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 241000710781 Flaviviridae Species 0.000 description 1
- 102100028701 General vesicular transport factor p115 Human genes 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 241000193385 Geobacillus stearothermophilus Species 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 241000709721 Hepatovirus A Species 0.000 description 1
- 241000700586 Herpesviridae Species 0.000 description 1
- 101000767151 Homo sapiens General vesicular transport factor p115 Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 241001138501 Salmonella enterica Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000949477 Toona ciliata Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241000710772 Yellow fever virus Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 108700010877 adenoviridae proteins Proteins 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 235000010633 broth Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- PPBOKXIGFIBOGK-BDTUAEFFSA-N bvdv Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)C(C)C)[C@@H](C)CC)C1=CN=CN1 PPBOKXIGFIBOGK-BDTUAEFFSA-N 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000000498 cooling water Substances 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 244000309457 enveloped RNA virus Species 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000002310 reflectometry Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000013595 supernatant sample Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 229940051021 yellow-fever virus Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Apparatus For Disinfection Or Sterilisation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/502,910 US6312931B1 (en) | 2000-02-11 | 2000-02-11 | Protecting molecules in biologically derived compositions while treating with high intensity broad-spectrum pulsed light |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200206591B true ZA200206591B (en) | 2003-07-01 |
Family
ID=23999921
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200206591A ZA200206591B (en) | 2000-02-11 | 2002-08-16 | Protecting molecules in biologically derived compositions while treating with broad-spectrum pulsed light. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6312931B1 (fr) |
| EP (1) | EP1261699A4 (fr) |
| JP (1) | JP2003521939A (fr) |
| KR (1) | KR20020092954A (fr) |
| CN (1) | CN1416465A (fr) |
| AU (2) | AU3678701A (fr) |
| BR (1) | BR0108260A (fr) |
| CA (1) | CA2399151A1 (fr) |
| WO (1) | WO2001059085A1 (fr) |
| ZA (1) | ZA200206591B (fr) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040067157A1 (en) * | 1993-07-22 | 2004-04-08 | Clearant, Inc. | Methods for sterilizing biological materials |
| US20040086420A1 (en) * | 2000-03-23 | 2004-05-06 | Macphee Martin J. | Methods for sterilizing serum or plasma |
| KR20030011279A (ko) * | 2000-03-23 | 2003-02-07 | 클리어런트, 인코포레이티드 | 생물학적 성분의 살균방법 |
| US6843961B2 (en) * | 2000-06-15 | 2005-01-18 | Gambro, Inc. | Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light |
| US9044523B2 (en) | 2000-06-15 | 2015-06-02 | Terumo Bct, Inc. | Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light |
| US20020015662A1 (en) * | 2000-06-15 | 2002-02-07 | Hlavinka Dennis J. | Inactivation of contaminants using photosensitizers and pulsed light |
| US6682695B2 (en) * | 2001-03-23 | 2004-01-27 | Clearant, Inc. | Methods for sterilizing biological materials by multiple rates |
| WO2002092806A1 (fr) * | 2001-05-15 | 2002-11-21 | V.I. Technologies, Inc. | Appareils permettant d'inactiver des pathogenes dans des fluides contenant des proteines |
| US6696060B2 (en) * | 2001-06-14 | 2004-02-24 | Clearant, Inc. | Methods for sterilizing preparations of monoclonal immunoglobulins |
| US6946098B2 (en) | 2001-08-10 | 2005-09-20 | Clearant, Inc. | Methods for sterilizing biological materials |
| US20030031584A1 (en) * | 2001-08-10 | 2003-02-13 | Wilson Burgess | Methods for sterilizing biological materials using dipeptide stabilizers |
| US7252799B2 (en) * | 2001-08-31 | 2007-08-07 | Clearant, Inc. | Methods for sterilizing preparations containing albumin |
| US6749851B2 (en) * | 2001-08-31 | 2004-06-15 | Clearant, Inc. | Methods for sterilizing preparations of digestive enzymes |
| US6783968B2 (en) * | 2001-09-24 | 2004-08-31 | Clearant, Inc. | Methods for sterilizing preparations of glycosidases |
| US20030185702A1 (en) * | 2002-02-01 | 2003-10-02 | Wilson Burgess | Methods for sterilizing tissue |
| US20030095890A1 (en) * | 2001-09-24 | 2003-05-22 | Shirley Miekka | Methods for sterilizing biological materials containing non-aqueous solvents |
| US20030124023A1 (en) * | 2001-12-21 | 2003-07-03 | Wilson Burgess | Method of sterilizing heart valves |
| WO2003094978A1 (fr) * | 2002-05-08 | 2003-11-20 | Millipore Corporation | Decontamination lumineuse d'un milieu de fermentation |
| US20040013561A1 (en) * | 2002-07-18 | 2004-01-22 | David Mann | Methods for sterilizing recombinant or transgenic material |
| US6908591B2 (en) * | 2002-07-18 | 2005-06-21 | Clearant, Inc. | Methods for sterilizing biological materials by irradiation over a temperature gradient |
| US20060222677A1 (en) * | 2004-01-14 | 2006-10-05 | Bianca Baroli | Method of protecting sensitive molecules from a photo-polymerizing environment |
| US9511344B2 (en) * | 2007-12-18 | 2016-12-06 | Ultraviolet Sciences, Inc. | Ultraviolet light treatment chamber |
| US9808544B2 (en) | 2005-08-31 | 2017-11-07 | Ultraviolet Sciences, Inc. | Ultraviolet light treatment chamber |
| US7511281B2 (en) * | 2005-08-31 | 2009-03-31 | Ultraviolet Sciences, Inc. | Ultraviolet light treatment chamber |
| US8834788B2 (en) * | 2006-05-04 | 2014-09-16 | Fogg Filler Company | Method for sanitizing/sterilizing a container/enclosure via controlled exposure to electromagnetic radiation |
| EP3187585A1 (fr) | 2010-03-25 | 2017-07-05 | Oregon Health&Science University | Glycoprotéines de cytomégalovirus (cmv) et vecteurs de recombinaison |
| PL2691530T3 (pl) | 2011-06-10 | 2019-02-28 | Oregon Health & Science University | Glikoproteiny i rekombinowane wektory CMV |
| US20130189754A1 (en) | 2011-09-12 | 2013-07-25 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
| US9402894B2 (en) | 2011-10-27 | 2016-08-02 | International Aids Vaccine Initiative | Viral particles derived from an enveloped virus |
| ES2631608T3 (es) | 2012-06-27 | 2017-09-01 | International Aids Vaccine Initiative | Variante de la glicoproteína Env del VIH-1 |
| US20150065381A1 (en) | 2013-09-05 | 2015-03-05 | International Aids Vaccine Initiative | Methods of identifying novel hiv-1 immunogens |
| EP2873423B1 (fr) | 2013-10-07 | 2017-05-31 | International Aids Vaccine Initiative | Trimères de glycoprotéines d'enveloppe du vih -1 soluble |
| EP3069730A3 (fr) | 2015-03-20 | 2017-03-15 | International Aids Vaccine Initiative | Trimères de glycoprotéines de l'enveloppe du vih-1 soluble |
| EP3072901A1 (fr) | 2015-03-23 | 2016-09-28 | International Aids Vaccine Initiative | Trimères de glycoprotéines de l'enveloppe du vih-1 soluble |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4910942A (en) * | 1983-11-23 | 1990-03-27 | Maxwell Laboratories, Inc. | Methods for aseptic packaging of medical devices |
| US4871559A (en) * | 1983-11-23 | 1989-10-03 | Maxwell Laboratories, Inc. | Methods for preservation of foodstuffs |
| US4880512A (en) * | 1984-02-16 | 1989-11-14 | Kollmorgen Corporation | Pulsed light selective photolysis process for treatment of biological media and products made thereby |
| DE3730533A1 (de) * | 1987-09-11 | 1989-03-30 | Biotest Pharma Gmbh | Verfahren zur sterilisation von plasma oder plasmafraktionen |
| AU3474593A (en) * | 1992-01-16 | 1993-08-03 | New York University | Hypericin treatment of vaccine agents for improved immunogenicity |
| US5489442A (en) * | 1994-04-18 | 1996-02-06 | Purepulse Technologies, Inc. | Prolongation of shelf-life in perishable food products |
| AU7430296A (en) | 1995-10-26 | 1997-05-15 | Purepulse Technologies, Inc. | Improved deactivation of organisms using high-intensity pulsed polychromatic light |
| US5768853A (en) * | 1996-02-15 | 1998-06-23 | Purepulse Technologies, Inc. | Deactivation of microorganisms |
| US5786598A (en) * | 1996-05-22 | 1998-07-28 | Purepulse Technologies, Inc. | Sterilization of packages and their contents using high-intensity, short-duration pulses of incoherent, polychromatic light in a broad spectrum |
| EP0793970A1 (fr) * | 1996-03-08 | 1997-09-10 | Rotkreuzstiftung Zentrallaboratorium Blutspendedienst Srk | Inactivation photodynamique de virus |
| US5730933A (en) * | 1996-04-16 | 1998-03-24 | Depuy Orthopaedics, Inc. | Radiation sterilization of biologically active compounds |
| IL122388A (en) * | 1997-12-01 | 2004-05-12 | Atlantium Lasers Ltd | Method and device for disinfecting liquids or gases |
-
2000
- 2000-02-11 US US09/502,910 patent/US6312931B1/en not_active Expired - Fee Related
-
2001
- 2001-02-08 WO PCT/US2001/004113 patent/WO2001059085A1/fr active Application Filing
- 2001-02-08 KR KR1020027010398A patent/KR20020092954A/ko not_active Application Discontinuation
- 2001-02-08 EP EP01908989A patent/EP1261699A4/fr not_active Withdrawn
- 2001-02-08 JP JP2001558225A patent/JP2003521939A/ja active Pending
- 2001-02-08 CN CN01806234A patent/CN1416465A/zh active Pending
- 2001-02-08 AU AU3678701A patent/AU3678701A/xx active Pending
- 2001-02-08 BR BR0108260-4A patent/BR0108260A/pt not_active Application Discontinuation
- 2001-02-08 CA CA002399151A patent/CA2399151A1/fr not_active Abandoned
- 2001-02-08 AU AU2001236787A patent/AU2001236787B2/en not_active Ceased
-
2002
- 2002-08-16 ZA ZA200206591A patent/ZA200206591B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001059085A1 (fr) | 2001-08-16 |
| KR20020092954A (ko) | 2002-12-12 |
| EP1261699A1 (fr) | 2002-12-04 |
| EP1261699A4 (fr) | 2008-01-23 |
| CA2399151A1 (fr) | 2001-08-16 |
| AU3678701A (en) | 2001-08-20 |
| JP2003521939A (ja) | 2003-07-22 |
| BR0108260A (pt) | 2003-03-05 |
| US6312931B1 (en) | 2001-11-06 |
| CN1416465A (zh) | 2003-05-07 |
| AU2001236787B2 (en) | 2006-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2001236787B2 (en) | Protecting molecules in biologically derived compositions while treating with broad-spectrum pulsed light | |
| AU2001236787A1 (en) | Protecting molecules in biologically derived compositions while treating with broad-spectrum pulsed light | |
| EP0873143B1 (fr) | Desactivation amelioree d'organismes utilisant une lumiere polychromatique pulsee a haute intensite | |
| RU2466742C2 (ru) | Способ инактивирования патогенов в донорской крови, плазме крови или концентратах эритроцитов в гибких контейнерах с помощью встряхивания | |
| EP1152773B1 (fr) | Inactivation de pathogenes par utilisation de lumiere pulsee a large spectre | |
| US8173066B2 (en) | Method for irradiating thrombocyte concentrates in flexible containers with ultra-violet light | |
| JP6283162B2 (ja) | ヒト血液及び血液製剤における微生物枯渇のための新たな方法 | |
| WO2017062260A2 (fr) | Inactivation d'agents pathogènes dans des produits sanguins ex vivo dans des poches de stockage à l'aide de la lumière visible | |
| US20020176796A1 (en) | Inactivation of microbes in biological fluids | |
| US20030129079A1 (en) | Method for protein-preserving purification of contaminated biological liquids | |
| WO1997033629A1 (fr) | Purification par ultraviolets de fluides biologiques, de serums sanguins et d'autres solutions contaminees | |
| JPS60188161A (ja) | 生物学的媒体の処理のためのパルス光による選択的光分解法 | |
| Desmarais | Pulsed White Light as a Tool for Disinfection | |
| MXPA98003230A (es) | Desactivacion mejorada de organismos usando luz policromatica pulsada, de alta intensidad |